 |
172 Diseases |  |
135 Trials |
|
135 Trials |  |
7089 News |  |
| «12...5758596061626364656667...7475» |
- Izervay (avacincaptad pegol intravitreal solution) / Astellas
Trial completion: A Study to Establish the Safety and Tolerability of Zimura (clinicaltrials.gov) - May 16, 2016
P2, N=5, Completed, Sponsor: Ophthotech Corporation
Active, not recruiting --> Completed
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study (clinicaltrials.gov) - May 16, 2016
P2, N=25, Completed, Sponsor: University Hospital, Bonn
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | PF582 (ranibizumab biosimilar) / Ligand
Trial completion, Trial primary completion date: Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration (clinicaltrials.gov) - May 11, 2016
P1/2, N=25, Completed, Sponsor: Pfenex, Inc
Active, not recruiting --> Completed Trial primary completion date: May 2016 --> Jan 2016 | Active, not recruiting --> Completed
- || Lucentis (ranibizumab) / Roche, Novartis
New P2/3 trial: Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy (clinicaltrials.gov) - May 11, 2016
P2/3, N=110, Not yet recruiting, Sponsor: Sun Yat-sen University
- ||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients (clinicaltrials.gov) - May 10, 2016
P3, N=381, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: May 2016 --> Jan 2016 | Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | PF582 (ranibizumab biosimilar) / Ligand
Enrollment closed, Trial primary completion date: Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration (clinicaltrials.gov) - May 5, 2016
P1/2, N=25, Active, not recruiting, Sponsor: Pfenex, Inc
Recruiting --> Active, not recruiting Completed --> Active, not recruiting | Trial primary completion date: Dec 2015 --> May 2016
- | Lucentis (ranibizumab) / Roche, Novartis
Enrollment open, Head-to-Head: RELIANCE: Head to Head Study of Anti-VEGF Treatment. (clinicaltrials.gov) - May 5, 2016
P4, N=12, Recruiting, Sponsor: Novartis Pharmaceuticals
Completed --> Active, not recruiting | Trial primary completion date: Dec 2015 --> May 2016 Not yet recruiting --> Recruiting
- |||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: MAKO: Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD (clinicaltrials.gov) - May 4, 2016
P3, N=650, Recruiting, Sponsor: Ohr Pharmaceutical Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Lucentis (ranibizumab) / Roche, Novartis
Phase classification, Surgery: OCTOPUS: Use of Ranibizumab With Mitomycin C During Trabeculectomy (clinicaltrials.gov) - Apr 20, 2016
P1/2, N=30, Completed, Sponsor: University of Colorado, Denver
Not yet recruiting --> Recruiting Phase classification: P=N/A --> P1/2
- Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Enrollment status, Trial primary completion date, Combination therapy, Monotherapy: To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema (clinicaltrials.gov) - Apr 19, 2016
P4, N=60, Enrolling by invitation, Sponsor: The University of Hong Kong
Phase classification: P=N/A --> P1/2 Recruiting --> Enrolling by invitation | Trial primary completion date: Dec 2015 --> Jun 2017
- ||| Fovista (pegpleranib) / Roche, Astellas
Enrollment closed, Combination therapy: A 24 Month Phase 2a Open Label, Randomized Study of Avastin (clinicaltrials.gov) - Apr 14, 2016
P2, N=64, Active, not recruiting, Sponsor: Ophthotech Corporation
Recruiting --> Enrolling by invitation | Trial primary completion date: Dec 2015 --> Jun 2017 Recruiting --> Active, not recruiting
- || Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME (clinicaltrials.gov) - Apr 13, 2016
P2, N=100, Recruiting, Sponsor: Arshad Khanani
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2016 --> Jan 2017
- hI-con1 (ICON-1) / Endpoint Health
Enrollment closed: EMERGE: Study Evaluating Intravitreal hI-con1 (clinicaltrials.gov) - Apr 13, 2016
P2, N=88, Active, not recruiting, Sponsor: Iconic Therapeutics, Inc.
Trial primary completion date: Jan 2016 --> Jan 2017 Recruiting --> Active, not recruiting
- Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion (clinicaltrials.gov) - Apr 7, 2016
P4, N=30, Recruiting, Sponsor: Nagoya City University
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2016 --> Apr 2018
- |||||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity (clinicaltrials.gov) - Apr 6, 2016
P3, N=300, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Sep 2016 --> Apr 2018 Not yet recruiting --> Recruiting
- || Vabysmo (faricimab-svoa) / Roche
Trial primary completion date: BOULEVARD: A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema (clinicaltrials.gov) - Apr 6, 2016
P2, N=150, Recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2018 --> Oct 2017
- |||||||||| Lucentis (ranibizumab) / Roche, Novartis
New P3 trial: MAKO: Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD (clinicaltrials.gov) - Apr 6, 2016
P3, N=650, Not yet recruiting, Sponsor: Ohr Pharmaceutical Inc.
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients. (clinicaltrials.gov) - Apr 4, 2016
P=N/A, N=300, Recruiting, Sponsor: NJ Retina
Trial primary completion date: Feb 2018 --> Oct 2017 Trial primary completion date: Jun 2016 --> Sep 2016
- |||| Vabysmo (faricimab-svoa) / Roche
Enrollment open: BOULEVARD: A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema (clinicaltrials.gov) - Apr 2, 2016
P2, N=150, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jun 2016 --> Sep 2016 Not yet recruiting --> Recruiting
- Avegra (bevacizumab biosimilar) / Biocad
Enrollment change, Trial withdrawal, Trial primary completion date: GALATIR: Safety and Efficacy Study of BCD-021 Compared to Lucentis (clinicaltrials.gov) - Mar 31, 2016
P3, N=0, Withdrawn, Sponsor: Biocad
Not yet recruiting --> Recruiting N=108 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> Mar 2016
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Trial primary completion date: Intravitreal Injections of Ranibizumab With Deferred Laser Grid Laser Photocoagulation for Treatment of Diabetic Macular Edema With Visual Impairment (clinicaltrials.gov) - Mar 30, 2016
P2, N=35, Completed, Sponsor: Poitiers University Hospital
N=108 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2017 --> Mar 2016 Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jul 2014
- Lucentis (ranibizumab) / Roche, Novartis
Trial termination: HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration (clinicaltrials.gov) - Mar 29, 2016
P2, N=40, Terminated, Sponsor: Anne Fung MD
Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jul 2014 Active, not recruiting --> Terminated; Drug dose became unavailable
- || Susvimo (ranibizumab port delivery system) / Roche, Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: LADDER: Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Mar 22, 2016
P2, N=220, Recruiting, Sponsor: Genentech, Inc.
Active, not recruiting --> Terminated; Drug dose became unavailable Trial primary completion date: Dec 2016 --> Oct 2017
- || LMG324 / Novartis, Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration (clinicaltrials.gov) - Mar 18, 2016
P1/2, N=106, Recruiting, Sponsor: Alcon Research
Trial primary completion date: Dec 2016 --> Oct 2017 Trial primary completion date: Feb 2017 --> Jun 2017
- Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Evaluation of Wet Age-Related Macular Degeneration (AMD) Genetic Profile Interactions With Ranibizumab Treatment Outcomes (clinicaltrials.gov) - Mar 18, 2016
P=N/A, N=70, Completed, Sponsor: McMaster University
Trial primary completion date: Feb 2017 --> Jun 2017 Recruiting --> Completed
- ||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment change, Trial primary completion date: SALT: Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD (clinicaltrials.gov) - Mar 16, 2016
P4, N=706, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed N=500 --> 706 | Trial primary completion date: Aug 2016 --> May 2017
- ||| ASP8232 / Astellas
Enrollment closed: A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME) (clinicaltrials.gov) - Mar 16, 2016
P2, N=96, Active, not recruiting, Sponsor: Astellas Pharma Europe B.V.
N=500 --> 706 | Trial primary completion date: Aug 2016 --> May 2017 Recruiting --> Active, not recruiting
- Lucentis (ranibizumab) / Roche, Novartis
Biomarker, New trial: Cytokeratin 8 Level in Age-related Macular Degeneration (clinicaltrials.gov) - Mar 14, 2016
P=N/A, N=40, Recruiting, Sponsor: Gangnam Severance Hospital
- || Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: SAFARI: Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD (clinicaltrials.gov) - Mar 9, 2016
P4, N=162, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2016 --> May 2017
- | Fumena (vorolanib) / Tyrogenex
Trial completion, Enrollment change: Pilot Study of X-82 in Patients With Wet AMD (clinicaltrials.gov) - Mar 9, 2016
P1/2, N=35, Completed, Sponsor: Tyrogenex
Trial primary completion date: Oct 2016 --> May 2017 Active, not recruiting --> Completed | N=20 --> 35
- Cimerli (ranibizumab-eqrn) / Amneal, Formycon, Coherus Biosci, Teva
Enrollment open: COLUMBUS-AMD: Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Mar 8, 2016
P3, N=0, Recruiting, Sponsor: Bioeq GmbH
Active, not recruiting --> Completed | N=20 --> 35 Not yet recruiting --> Recruiting
- ||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open, Trial primary completion date: LUMINOUS: Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting (clinicaltrials.gov) - Mar 5, 2016
P=N/A, N=30000, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting | Trial primary completion date: Dec 2016 --> Mar 2016
- ||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization. (clinicaltrials.gov) - Mar 4, 2016
P3, N=183, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Recruiting | Trial primary completion date: Dec 2016 --> Mar 2016 Active, not recruiting --> Completed
- ||| Lucentis (ranibizumab) / Roche, Novartis
New P3 trial: A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis (clinicaltrials.gov) - Mar 4, 2016
P3, N=30, Recruiting, Sponsor: Genentech, Inc.
- ||||| Vabysmo (faricimab-svoa) / Roche
New P2 trial: BOULEVARD: A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema (clinicaltrials.gov) - Mar 4, 2016
P2, N=150, Not yet recruiting, Sponsor: Hoffmann-La Roche
- ||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment open: Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis (clinicaltrials.gov) - Mar 2, 2016
P=N/A, N=300, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD) (clinicaltrials.gov) - Feb 27, 2016
P3, N=100, Completed, Sponsor: Genentech, Inc.
Not yet recruiting --> Recruiting No longer recruiting --> Completed
- ||||||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion: A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration (clinicaltrials.gov) - Feb 27, 2016
P3, N=720, Completed, Sponsor: Genentech, Inc.
No longer recruiting --> Completed No longer recruiting --> Completed
- |||| Lucentis (ranibizumab) / Roche, Novartis
Trial completion, Combination therapy: Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD) (clinicaltrials.gov) - Feb 27, 2016
P1/2, N=168, Completed, Sponsor: Genentech, Inc.
No longer recruiting --> Completed No longer recruiting --> Completed
- ||| Eylea (aflibercept intravitreal) / Bayer, Regeneron
Enrollment open: TITAN: Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD (clinicaltrials.gov) - Feb 26, 2016
P=N/A, N=225, Recruiting, Sponsor: Bayer
No longer recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Ozurdex (dexamethasone intravitreal implant) / AbbVie, Lucentis (ranibizumab) / Roche, Novartis
New P4 trial, Monotherapy: COLLIDE: Combination OZURDEX (clinicaltrials.gov) - Feb 17, 2016
P4, N=60, Recruiting, Sponsor: North Toronto Eye Care Laser and Eye Specialists
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: SHIFT-2: Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections (clinicaltrials.gov) - Feb 16, 2016
P4, N=200, Recruiting, Sponsor: St. Michael's Hospital, Toronto
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2015 --> Sep 2017
- Lucentis (ranibizumab) / Roche, Novartis
Enrollment open, Trial initiation date, Trial primary completion date: Analysis of Aqueous and Vitreous Humor (clinicaltrials.gov) - Feb 10, 2016
P2, N=45, Recruiting, Sponsor: California Retina Consultants
Trial primary completion date: Dec 2015 --> Sep 2017 Not yet recruiting --> Recruiting | Initiation date: Mar 2014 --> Jul 2015 | Trial primary completion date: Jun 2014 --> Jul 2017
- ||| Lucentis (ranibizumab) / Roche, Novartis
Enrollment closed: Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200 (clinicaltrials.gov) - Feb 4, 2016
P4, N=347, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Initiation date: Mar 2014 --> Jul 2015 | Trial primary completion date: Jun 2014 --> Jul 2017 Recruiting --> Active, not recruiting
- Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: ERASER: Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab (clinicaltrials.gov) - Feb 2, 2016
P2/3, N=60, Recruiting, Sponsor: California Retina Consultants
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2016 --> Dec 2017
- ||||| Lucentis (ranibizumab) / Roche, Novartis
Clinical protocol, Enrollment closed, Enrollment change, Trial primary completion date: ECLIPSE: An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. (clinicaltrials.gov) - Feb 2, 2016
P3, N=260, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Active, not recruiting | N=500 --> 260 | Trial primary completion date: Dec 2018 --> Mar 2016
- || Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis (clinicaltrials.gov) - Feb 2, 2016
P=N/A, N=300, Not yet recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | N=500 --> 260 | Trial primary completion date: Dec 2018 --> Mar 2016 Trial primary completion date: Dec 2015 --> Jun 2016
- Lucentis (ranibizumab) / Roche, Novartis
Trial primary completion date: TIDE AMD: Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - Feb 2, 2016
P4, N=40, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: May 2016 --> Nov 2016
- Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
New trial: OPHTH-010915: Aflibercept in Recurrent or Persistent CNV (clinicaltrials.gov) - Feb 1, 2016
P=N/A, N=20, Recruiting, Sponsor: Medical University of Vienna
- Ozurdex (dexamethasone intravitreal implant) / AbbVie
Trial primary completion date: DIME: Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema (clinicaltrials.gov) - Jan 28, 2016
P4, N=40, Recruiting, Sponsor: California Retina Consultants
Trial primary completion date: May 2016 --> Nov 2016 Trial primary completion date: Jul 2016 --> Dec 2016